Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:11934 |
Name | head and neck cancer |
Definition | An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer head and neck cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK wild-type | Cisplatin + Dalantercept | head and neck cancer | predicted - sensitive | detail... |
ATM loss | AZD6738 + Olaparib | head and neck cancer | predicted - sensitive | detail... |
Unknown unknown | Cisplatin + GL-ONC1 + Radiotherapy | head and neck cancer | not applicable | detail... |
BRAF G469A | Ulixertinib | head and neck cancer | sensitive | detail... |
PIK3CA mutant | Alpelisib | head and neck cancer | sensitive | detail... |
ATM del | AZD7648 + Olaparib | head and neck cancer | sensitive | detail... |
Unknown unknown | AsiDNA | head and neck cancer | not applicable | detail... |
Unknown unknown | AsiDNA + Olaparib | head and neck cancer | not applicable | detail... |
ATM del | AZD7648 | head and neck cancer | sensitive | detail... |
ATM del | Olaparib | head and neck cancer | sensitive | detail... |
Unknown unknown | AZD7648 + Olaparib | head and neck cancer | not applicable | detail... |
Unknown unknown | Olaparib | head and neck cancer | not applicable | detail... |
Unknown unknown | AZD7648 | head and neck cancer | not applicable | detail... |
Unknown unknown | Cetuximab + Ficlatuzumab | head and neck cancer | not applicable | detail... |
Unknown unknown | NT219 + Pembrolizumab | head and neck cancer | not applicable | detail... |
Unknown unknown | Cetuximab + NT219 | head and neck cancer | not applicable | detail... |
Unknown unknown | TG6002 | head and neck cancer | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00903461 | Phase Ib/II | EGFR Antisense DNA | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT00970502 | Phase Ib/II | Celecoxib + Erlotinib | Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | Completed | USA | 0 |
NCT00978250 | Phase II | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | Completed | USA | 0 |
NCT01218048 | Phase II | Cisplatin Carboplatin Cetuximab | ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | 2 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01588431 | Phase II | Cetuximab + Cisplatin + Docetaxel Bevacizumab | Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | 2 |
NCT01835626 | Phase II | Vismodegib | Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma | Completed | USA | 0 |
NCT01874860 | Phase I | Doxycycline | Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients | Recruiting | USA | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Recruiting | USA | CAN | 13 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | 6 |
NCT02004106 | Phase I | Cergutuzumab amunaleukin | A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | Completed | USA | 7 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02051751 | Phase I | Alpelisib + Paclitaxel | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | Completed | USA | 3 |
NCT02107235 | Phase I | Cisplatin Rigosertib Sodium | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | Completed | USA | 0 |
NCT02113878 | Phase I | Buparlisib + Cisplatin | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | Active, not recruiting | USA | 0 |
NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Active, not recruiting | USA | 8 |
NCT02471846 | Phase I | GDC-0919 Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 3 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Active, not recruiting | USA | 10 |
NCT02538627 | Phase I | Seribantumab MM-151 | Phase 1 Combination Study of MM-151 and MM-121 | Terminated | USA | 0 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02646319 | Phase I | Nab-Rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02671955 | Phase I | JNJ-61610588 | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02710396 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Genetic Predictors of Benefit to Pembrolizumab | Active, not recruiting | USA | 0 |
NCT02841748 | Phase II | Pembrolizumab | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | Recruiting | USA | 0 |
NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
NCT03109873 | Phase I | Metformin | Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer | Completed | USA | 0 |
NCT03207867 | Phase II | PBF-509 + Spartalizumab | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Recruiting | USA | 13 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03355560 | Phase II | Nivolumab | Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy | Active, not recruiting | USA | 0 |
NCT03578432 | Phase I | Everolimus | Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy | Terminated | USA | 0 |
NCT03621982 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Recruiting | USA | 0 |
NCT04044859 | Phase I | ADP-A2M4 cells | Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors | Recruiting | USA | CAN | 2 |
NCT04065555 | Phase I | Avelumab + TAK-981 Cetuximab Cetuximab + TAK-981 TAK-981 Avelumab | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Recruiting | USA | 0 |
NCT04105543 | Phase I | CLR 131 | CLR 131 Combined With Radiation for Head and Neck Cancer | Recruiting | USA | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Recruiting | USA | 1 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Recruiting | USA | 2 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04574583 | Phase Ib/II | FPV-CV301 + M7824 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Recruiting | USA | 0 |
NCT04624113 | Phase Ib/II | Pembrolizumab + Tazemetostat | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Not yet recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |